We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Bilirubin Improves Risk Prediction of Cardiovascular Death

By LabMedica International staff writers
Posted on 07 Jan 2019
Diabetes is one of the most prevalent disorders worldwide and cardiovascular (CV) disease is the leading cause of mortality and morbidity in diabetic patients. More...
Therefore, improvements in risk prevention and adequate treatment are needed in these high-risk subjects.

Previous studies have shown that elevated serum bilirubin concentrations might protect against atherosclerosis, yet it remains unclear whether higher serum bilirubin concentrations work in favor of the cardiovascular system in patients with type 2 diabetes.

A team of scientists led by those at the National Yang-Ming University (Taipei, Taiwan, ROC) enrolled 2,936 subjects with type 2 diabetes (1,009 males and 1,927 females; mean age of 62.7 ± 11 years). The goal of the study was to investigate the association between serum bilirubin and subsequent development of cardiovascular death among asymptomatic diabetic patients.

Blood samples were obtained from all patients after an overnight fast of more than 12 hours. Total bilirubin was measured using a Hitachi 7600 chemistry analyzer with a vanadate oxidation method. Lipid profiles including triglycerides, total cholesterol, high-density lipoprotein (HDL), low-density lipoprotein (LDL) cholesterol, serum total bilirubin, albumin, creatinine, aspartate transaminase (AST), alanine transaminase (ALT, and glucose were also measured at the same time.

The team followed the patients for 5.4 ± 3.0 years, and there were 218 deaths including 95 cardiovascular deaths. The occurrence of CV death and all-cause death were negatively correlated with increasing serum bilirubin quintiles and actual bilirubin values. Serum bilirubin was negatively associated with incident cardiovascular death and all-cause death. The addition of bilirubin for cardiovascular death increased the C-statistic from 0.713 to 0.729 and showed an integrated discrimination improvement (IDI) of 0.012 with 8.57% improvement in net reclassification analysis.

The authors concluded that higher serum concentrations of bilirubin are associated with a decreased risk of developing CV and all-cause death in diabetic patients. Bilirubin improved the risk prediction of cardiovascular death but provided only a slightly better prediction of all-cause death than conventional risk factors. The study was published in the January 2019 issue of the journal Clinica Chimica Acta.

Related Links:
National Yang-Ming University


Gold Member
Collection and Transport System
PurSafe Plus®
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Autoimmune Liver Diseases Assay
Microblot-Array Liver Profile Kit
Automatic Hematology Analyzer
DH-800 Series
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Noul’s AI-based cervical cancer diagnostic solution, miLab CER (Photo courtesy of Noul)

AI-Powered Cervical Cancer Test Set for Major Rollout in Latin America

Noul Co., a Korean company specializing in AI-based blood and cancer diagnostics, announced it will supply its intelligence (AI)-based miLab CER cervical cancer diagnostic solution to Mexico under a multi‑year... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.